Secondary Logo

Journal Logo

Sugammadex–Rocuronium Dosing

Section Editor(s): Saidman, LawrenceKopman, Aaron F. MD

doi: 10.1213/01.ane.0000269685.86443.a8
Letters to the Editor: Letters & Announcements

Department of Anesthesiology (N.R. 408); Saint Vincent's Hospital Manhattan; New York, NY; or

Back to Top | Article Outline

To the Editor:

In their recent dose-finding study, Groudine et al. (1) note that the molecular weight of sugammadex is 3.6 times that of rocuronium. They postulate that these drugs bind in a 1:1 ratio, and that as a result 1.8 mg/kg sugammadex should encapsulate all the rocuronium administered in a 0.50 mg/kg dose.

This hypothesis is perhaps overly simplistic as it does not explain all available clinical data. Following rocuronium 1.2 mg/kg, sugammadex 4.0 mg/kg does not produce prompt and complete neuromuscular block if administered 3 min (2) or 5 min later (3). Until all the data are in, I would suggest that it is premature to suggest that when sugammadex and rocuronium are administered in equimolar amounts that complete reversal of neuromuscular block will necessarily ensue.

Aaron F. Kopman, MD

Department of Anesthesiology (N.R. 408)

Saint Vincent's Hospital Manhattan

New York, NY or

Back to Top | Article Outline


1. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007;104:555–62
2. Rex C, Khuenl-Brady K, Sielenkaemper A, Kjaer CC, Puehringer FK. Reversal of high-dose rocuronium (1.2 mg/kg) with org 25969. Anesthesiology 2005;103:A1129
3. de Boer H, Marcus M, Schouten P, Heeringa M, Driessen J. Reversal of rocuronium-induced (1.2 mg · kg−1) neuromuscular block by org 25969: a multi center dose finding and safety study. Anesthesiology 2005;103:A1117
© 2007 International Anesthesia Research Society